Amendment to the Claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

1. (currently amended) A compound of the following formula



wherein:

Z is N;

Y is $CONR^5$, NR^5CO, SO_2NR^5, NR^5SO_2, CH_2NR^5, NR^5CONR^5, CH_2CO, CO or CH_2O;

X is N;

P is phenyl;

Q is $C_{1\text{-}6}$alkyl;

R is $C_{0\text{-}6}$alkyl$(SO_2)NR^1R^2$;

R^1 and R^2 together form a ~~substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring~~ 1-pyrrolidinyl or 1-piperazinyl moiety, wherein said 1-pyrrolidinyl or 1-piperazinyl moiety may be optionally substituted by A;

R^4 is independently selected from CN, OR^6, $CONR^6R^7$, NR^6COR^7, $(SO)NR^6R^7$, SO_2R^6, phenyl, ~~a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated~~ 1-imidazolyl, 1-imidazolidinyl, 4-morpholinyl, 1-oxopyrrolidinyl, 1-piperazinyl, 1-pyrrolinyl, 2-thienyl moiety, [[and]]wherein said phenyl ring or ~~5 or 6 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring~~ ~~unsaturated~~1-imidazolyl, 1-

imidazolidinyl, 4-morpholinyl, 1-oxopyrrolidinyl, 1-piperazinyl, 1-pyrrolinyl, 2-thienyl moiety may be optionally be substituted ~~by one or more~~ with A;
n is 1;
R^5 is hydrogen or C_{1-6}alkyl;
R^6 and R^7 are independently selected from hydrogen, or C_{1-6}alkyl
A is oxo (=O), nitro, OR^6 or C_{1-6}alkyl;
as a free base or a pharmaceutically acceptable thereof.

Claims 2 and 3 (cancelled).

4. (currently amended) A compound according to claim [[3]]1, wherein said ~~heterocyclic ring comprises one or more N heteroatoms and said heterocyclic ring~~ R^4 is 1-piperazinyl [[is]] optionally substituted by A, ~~preferably~~ which A is a C_{1-6}alkyl.

5. (currently amended) A compound according to any one of claims 1[[, 3]] or 4, wherein Y is $CONR^5$; and R^5 is hydrogen~~; Q is C_{1-6}alkyl; R^4 is selected from: phenyl, 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S which heterocyclic group may be saturated or unsaturated, CN, OR^6, SO_2R^6, $NR^6(CO)R^7$, $(SO_2)NR^6R^7$, and $CONR^6R^7$; and n is 1; said phenyl or 5 or 6 membered heterocyclic ring optionally substituted by A~~.

6. (cancelled).

7. (currently amended) A compound according to claim 1 which is
3-Amino-*N*-(2-cyanoethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;
3-Amino-*N*-(3-amino-3-oxopropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;
3-Amino-*N*-(2-nitrobenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;
3-Amino-*N*-(2-methoxybenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-(3-morpholin-4-ylpropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide[[;]], or

3-Amino-*N*-[3-(4-methylpiperazin-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

as a free base or a pharmaceutically acceptable salt, ~~solvate or solvate of a salt~~ thereof~~;~~

~~3-Amino-*N*-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-*N*-[3-(1*H*-imidazol-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-*N*-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-*N*-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide hydrochloride;~~

~~3-Amino-*N*-(cyanomethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide dihydrochloride;~~

~~3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(1*H*-pyrrol-1-yl)ethyl]-2-pyrazinecarboxamide hydrochloride;~~

~~3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(methylsulfonyl)ethyl]-2-pyrazinecarboxamide hydrochloride;~~

~~*N*-[2-(Acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;~~

~~3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(2-oxo-1-imidazolidinyl)ethyl]-2-pyrazinecarboxamide hydrochloride;~~
~~3-Amino-*N*-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;~~
~~or as a free base or an alternative pharmaceutically acceptable salt thereof~~.

8. (currently amended) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of [[the]]a compound according to any one of claims 1 [[or 7]], 4, 7 or 35 in association with a pharmaceutically acceptable carrier[[s]] or diluent[[s]].

Claims 9 to 16. (Cancelled)

17. (withdrawn) A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

18. (withdrawn) A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

19. (withdrawn) The method according to claim 18, wherein the prevention and/or treatment is for Alzheimer's Disease.

20. (withdrawn) A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalitic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke,

head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders,
comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

21. (withdrawn) The method according to claim 18, wherein the prevention and/or treatment is of Type I or Type II diabetes, diabetic neuropathy or diabetes related disorders.

22. (withdrawn) A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

23. (withdrawn) A process for the preparation of a compound of formula **I** according to claim 1, wherein Y, X, Z, P, Q, R, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, A, m and n are defined as in formula **I**, comprising of de-halogen coupling of a compound of formula **IV** with an appropriate aryl species;



(IV) **(I)**

to give a compound of formula **I**.

24. (withdrawn) A process for the preparation of a compound of formula **I** according to claim 1, wherein Y, X, Z, P, Q, R, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, A, m and n are defined as in formula **I**, comprising reacting of a compound of formula **XXII**:



(XXII) **(I)**

wherein the reaction is being performed by activation of a compound of formula **XXII** by treatment with a coupling agent or with an acyl halide reagent followed by treatment with the appropriate amine, followed by cleavage of the solid phase moiety by treatment with an suitable acid in a suitable solvent, and where the reaction temperature is between 0 °C and reflux, to give a compound of formula **I**.

25 and 26. (cancelled)

27. (withdrawn) A compound which is
4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;
4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;
as a free base or a salt, solvate or solvate of a salt thereof.

28. (withdrawn) A compound of formula **IV**



(IV)

wherein

Y is $CONR^5$, NR^5CO, SO_2NR^5, NR^5SO_2, CH_2NR^5 NR^5CONR^5, CH_2CO, CO or CH_2O;

X is CH or N;

Z is N;

Q is C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl;

R^4 is independently selected from halogen, nitro, CHO, CN, OC_{1-6}alkylCN, OR^6, OC_{1-6}alkylOR^6, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, NR^6R^7, OC_{1-6}alkylNR^6R^7, NR^6OR^7, CO_2R^6, OC_{1-6}alkylCO_2R^6, $CONR^6R^7$, OC_{1-6}alkyl$CONR^6R^7$, OC_{1-6}alkyl$NR^6(CO)R^7$, $NR^6(CO)R^7$, $O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, COR^6, OC_{1-6}alkylCOR^6, $NR^6(CO)(CO)R^6$, $NR^6(CO)(CO)NR^6R^7$, SR^6, $(SO_2)NR^6R^7$, OC_{1-6}alkyl$NR^6(SO_2)R^7$, OC_{0-6}alkyl$(SO_2)NR^6R^7$, $(SO)NR^6R^7$, OC_{1-6}alkyl$(SO)NR^6R^7$, SO_3R^6, $NR^6(SO_2)NR^6R^7$, $NR^6(SO)R^7$, OC_{1-6}alkyl$NR^6(SO)R^7$, OC_{0-6}alkylSO_2R^6, SO_2R^6, SOR^6, C_{3-6}cycloalkyl, phenyl, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S wherein any C_{3-6}cycloalkyl, phenyl, 5 or 6 membered heteroaromatic ring with one or two heteroatoms selected independently from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by one or more A;

R^5 is hydrogen or C_{1-6}alkyl

R^6 and R^7 are independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl and C_{1-6}alkylNR^8R^9;

R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH_2 group may optionally be replaced by a CO group;

R^8 and R^9 are independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl and C_{0-6}alkylheteroaryl;

R^8 and R^9 may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

Hal is halogen;

n is 0, 1, 2, 3 or 4;

A is halogen, oxo (=O), nitro, CHO, CN, OR^6, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C_{0-6}alkylNR^6R^7, OC_{1-6}alkylNR^6R^7, CO_2R^8, $CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, COR^6, SR^6, $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, SO_3R^6, SO_2R^6 or SOR^6;

as a free base or a salt, solvate or solvate of a salt thereof.

29. (withdrawn) A compound according to claim 28, wherein

Y is $CONR^5$;

X is N;

Q is C_{1-6}alkyl;

R^4 is independently selected from CN, OR^6, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, wherein any 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by A;

R^5 is hydrogen;

R^6 is, C_{1-6}alkyl;

n is 1;

A is oxo (=O);

as a free base or a salt, solvate or solvate of a salt thereof.

30. (withdrawn) A compound which is

3-Amino-6-bromo-*N*-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[2-(1*H*-imidazol-4-yl)ethyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[3-(1*H*-imidazol-1-yl)propyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(2-methoxyethyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(3-methoxypropyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(cyanomethyl)pyrazine-2-carboxamide;

as a free base or a salt, solvate or solvate of a salt thereof.

31. (withdrawn) A compound of formula **XXII**



(XXII)

wherein:

Z is N;

X is CH or N;

P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S;

R is CHO, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C_{0-6}alkyl$(SO_2)NR^1R^2$, OC_{0-6}alkyl$(SO_2)NR^1R^2$, OC_{1-6}alkyl$(SO)NR^1R^2$, C_{1-6}alkyl$(SO)NR^1R^2$, C_{0-6}alkyl$NR^1(SO)R^2$, OC_{1-6}alkyl$NR^1(SO)R^2$, C_{0-6}alkyl$NR^1(SO_2)NR^1R^2$, OC_{1-6}alkyl$NR^1(SO_2)R^2$, C_{0-6}alkyl$(SO_2)C_{1-6}$alkylNR^1R^2, OC_{0-6}alkyl$(SO_2)C_{1-6}$alkylNR^1R^2, C_{0-6}alkyl$(SO)C_{1-6}$alkylNR^1R^2, OC_{1-6}alkyl$(SO)C_{1-6}$alkylNR^1R^2, C_{0-6}alkylSC_{1-6}alkylNR^1R^2, OC_{1-6}alkylSC_{1-6}alkylNR^1R^2, OC_{1-6}alkylOC_{1-6}alkyl, C_{1-6}alkylOC_{1-6}alkylNR^1R^2, OC_{1-6}alkylOC_{1-6}alkylNR^1R^2, C_{0-6}alkyl$CONR^{10}R^{11}$, OC_{0-6}alkyl$CONR^1R^2$, OC_{1-6}alkylNR^1R^2, C_{0-6}alkyl$NR^{10}(CO)R^{11}$, OC_{1-6}alkyl$NR^1(CO)R^2$, C_{0-6}alkyl$NR^{11}(CO)R^{10}$, C_{0-6}alkylCOR^{11}, OC_{1-6}alkylCOR^1, C_{0-6}alkyl$NR^{10}R^{11}$, C_{0-6}alkyl$O(CO)R^{11}$, OC_{1-6}alkyl$O(CO)R^1$, C_{0-6}alkyl$C(NR^{10})NR^{10}R^{11}$, C_{0-6}alkyl$C(NR^{11})N(R^{10})_2$, OC_{0-6}alkyl$C(NR^1)NR^1R^2$, C_{0-6}alkyl$NR^{10}(CO)OR^{11}$, OC_{1-6}alkyl$NR^1(CO)OR^2$, C_{0-6}alkyl$NR^{11}(CO)OR^{10}$, OC_{1-6}alkylCN, NR^1OR^2, C_{0-6}alkyl$(CO)OR^8$, OC_{1-6}alkyl$(CO)OR^1$, $NR^1(CO)NR^1R^2$, $NR^1(CO)(CO)R^2$, $NR^1(CO)(CO)NR^1R^2$, OR^{12} or SO_3R^1;

R^1 and R^2 are independently selected from hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylheterocycloalkyl, C_{1-6}alkylNR^6R^7, C_{0-6}alkylaryl and C_{0-6}alkylheteroaryl, wherein any C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylheterocycloalkyl, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl may be substituted by one or more A;

R^1 and R^2 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

R^3 is independently selected from halogen, nitro, CHO, C_{0-6}alkylCN, OC_{1-6}alkylCN, C_{0-6}alkylOR^6, OC_{1-6}alkylOR^6, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C_{0-6}alkylNR^6R^7, OC_{1-6}alkylNR^6R^7, OC_{1-6}alkylOC_{1-6}alkylNR^6R^7, NR^6OR^7, C_{0-6}alkylCO_2R^6, OC_{1-6}alkylCO_2R^6, C_{0-6}alkyl$CONR^6R^7$, OC_{1-6}alkyl$CONR^6R^7$, OC_{1-6}alkyl$NR^6(CO)R^7$, C_{0-6}alkyl$NR^6(CO)R^7$, $O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, C_{0-6}alkylCOR^6, OC_{1-6}alkylCOR^6,

$NR^6(CO)(CO)R^6$, $NR^6(CO)(CO)NR^6R^7$, SR^6, $C_{0-6}alkyl(SO_2)NR^6R^7$, $OC_{1-6}alkylNR^6(SO_2)R^7$, $OC_{0-6}alkyl(SO_2)NR^6R^7$, $C_{0-6}alkyl(SO)NR^6R^7$, $OC_{1-6}alkyl(SO)NR^6R^7$, SO_3R^6, $C_{0-6}alkylNR^6(SO_2)NR^6R^7$, $C_{0-6}alkylNR^6(SO)R^7$, $OC_{1-6}alkylNR^6(SO)R^7$, $OC_{0-6}alkylSO_2R^6$, $C_{0-6}alkylSO_2R^6$, $C_{0-6}alkylSOR^6$, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$, wherein any $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$ may be optionally substituted by one or more A;

R^6 and R^7 are independently selected from hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$, $C_{0-6}alkylheteroaryl$ and $C_{1-6}alkylNR^8R^9$;

R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH_2 group may optionally be replaced by a CO group;

R^8 and R^9 are independently selected from hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$;

R^8 and R^9 may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

R^{10} is hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$, $C_{0-6}alkylheteroaryl$ or $C_{1-6}alkylNR^8R^9$;

R^{11} is $C_{1-6}alkylNR^8R^9$;

R^{10} and R^{11} may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

A is halogen, oxo (=O), nitro, CHO, CN, OR^6, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}alkylNR^6R^7$, $OC_{1-6}alkylNR^6R^7$, CO_2R^8, $CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, COR^6, SR^6, $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, SO_3R^6, SO_2R^6 or SOR^6;

m is 0, 1, 2, 3 or 4;

as a free base or a salt, solvate or solvate of a salt thereof.

32. (withdrawn) A compound according to claim 31, wherein:

X is N;

P is phenyl;

R is $C_{0\text{-}6}$alkyl(SO_2)NR^1R^2;

R^1 and R^2 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S;

m is 0;

as a free base or a salt, solvate or solvate of a salt thereof.

33. (withdrawn) A compound which is

Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;

3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;

as a free base or a salt, solvate or solvate of a salt thereof.

34. (Cancelled).

35. (new) A compound according to claim 1 which is

3-Amino-*N*-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[3-(1*H*-imidazol-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;
3-Amino-*N*-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;
3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide hydrochloride;
3-Amino-*N*-(cyanomethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide dihydrochloride;
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(1*H*-pyrrol-1-yl)ethyl]-2-pyrazinecarboxamide hydrochloride;
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(methylsulfonyl)ethyl]-2-pyrazinecarboxamide hydrochloride;
N-[2-(Acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(2-oxo-1-imidazolidinyl)ethyl]-2-pyrazinecarboxamide hydrochloride;
3-Amino-*N*-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;
or a free base of any said hydrochloride or a pharmaceutically acceptable salt of any said free base.

36. (new) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of a compound according to claim 5 in association with a pharmaceutically acceptable carrier or diluent.